Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug;8(4):272-278.
doi: 10.1177/1756287216645314. Epub 2016 May 2.

What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence

Rachel Hu  1 , Daniel J George  1 , Tian Zhang  2
Affiliations
Review

What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence

Rachel Hu et al. Ther Adv Urol. 2016 Aug.

Abstract

Prostate cancer is the most common cancer in men and the second most deadly. About one-third of patients with prostate cancer will develop metastatic disease. We discuss the six United States Food and Drug Administration (FDA) approved treatments for metastatic castrate-resistant prostate cancer (mCRPC) with a strong focus on sipuleucel-T. Sipuleucel-T is the first immunotherapy shown to improve survival in asymptomatic or minimally-symptomatic mCRPC. Herein, we discuss the proposed mechanism of sipuleucel-T and its synthesis. We describe in detail the three randomized controlled trials (RTCs) that led to its approval. We also compiled the newest research regarding use of sipuleucel-T with other agents and in different patient populations. Finally, we discuss the current ongoing trials.

Keywords: PROvenge; metastatic castration-resistant prostate cancer; prostate cancer; sipuleucel-T.

PubMed Disclaimer

Conflict of interest statement

DJG serves on the speakers bureau for Dendreon. The authors declare no other conflicts of interest.

References

    1. Antonarakis E., Kibel A., Adams G., Karsh L., Elfiky A., Shore N., et al. (2015) Antigen-specific immune responses through 24 months in the stand trial: a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC). J Clin Oncol 33: 171.
    1. Beer T., Armstrong A., Rathkopf D., Loriot Y., Sternberg C., Higano C., et al. (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371: 424–433. - PMC - PubMed
    1. Beer T., Bernstein G., Corman J., Glode L., Hall S., Poll W., et al. (2011) Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 17: 4558–4567. - PubMed
    1. De Bono J., Logothetis C., Molina A., Fizazi K., North S., Chu L., et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995–2005. - PMC - PubMed
    1. De Bono J., Oudard S., Ozguroglu M., Hansen S., Machiels J., Kocak I., et al. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376: 1147–1154. - PubMed

LinkOut - more resources